About: COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Creator	Basta, Giuseppina Annamaria, Vianello Chiara, Caselli Giuseppina, Basta Phd, Serena Rosetta, Ragusa Turco, Del Turco, Serena
Source	Elsevier; PMC
abstract	A Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has become a pandemic disease named Coronavirus Disease-19 (COVID-19) of epochal dimension. The clinical spectrum of COVID-19 is wide, ranging from asymptomatic forms to severe pneumonia, sepsis and multiple organ dysfunction syndromes resulting in poor outcomes. Among the various consequences of severe COVID-19, cardiovascular (CV) collapse appears the most serious and potentially lethal. On the other hand, pre-existent CV comorbidities are also associated with higher mortality. The most reliable hypothetical pathogenetic mechanism for CV complications and cardiac injury in severe COVID-19 patients appears to be a sustained endothelial dysfunction, caused by the interplay of inflammation and coagulation. In this review, we survey papers addressing issues related to severe COVID-19, characterized by enhanced lung microvascular loss, hypercytokinemia, hypoxemia and thrombosis. We discuss about how the virus-induced downregulation of the angiotensin converting enzyme-2 (ACE2) receptor, used to enter the host cell, could affect the renin-angiotensin system, attempting to clarify the doubts about the use of ACE inhibitors and Angiotensin-II receptor blockers in COVID-19 patients. Finally, we point out how the delicate and physiological homeostatic function of the endothelium, which turns into a disastrous battlefield of the complex interaction between “cytokine and coagulative storms”, can be irreparably compromised and result in systemic inflammatory complications.
has issue date	2020-08-27(xsd:dateTime)
bibo:doi	10.1016/j.thromres.2020.08.039
has license	no-cc
sha1sum (hex)	dae10d50ad48c091b58f7608ffeacc5f52ef7e56
schema:url	https://doi.org/10.1016/j.thromres.2020.08.039
resource representing a document's title	COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
has PubMed Central identifier	PMC7451195
schema:publication	Thromb Res
resource representing a document's body	covid:dae10d50ad48c091b58f7608ffeacc5f52ef7e56#body_text
is schema:about of	named entity 'severe' named entity 'ranging' named entity 'endothelial dysfunction' covid:arg/dae10d50ad48c091b58f7608ffeacc5f52ef7e56 named entity 'proinflammatory' named entity 'endothelial' named entity 'endothelial activation' named entity 'ACEIs' named entity 'ACE2' named entity 'vWF' named entity 'histones' named entity 'spike protein' named entity 'China' named entity 'vascular endothelial' named entity 'COVID' named entity 'ACE2' named entity 'inflammation' named entity 'ACEIs' named entity 'risk factors' named entity 'meta-analysis' named entity 'serine' named entity 'ADAMTS13' named entity 'fatality rate' named entity 'CVD' named entity 'integral transmembrane protein' named entity 'hypoxia' named entity 'vasodilators' named entity 'intracellular' named entity 'bloodstream' named entity 'lung alveoli' named entity 'coagulation cascade' named entity 'hypoxia' named entity 'ADAM17' named entity 'ACE2' named entity 'ACE2 receptor' named entity 'complement' named entity 'COVID-19' named entity 'neutrophilia' named entity 'endothelial' named entity 'receptor for advanced glycation endproducts' named entity 'infection' named entity 'COVID' named entity 'acidosis' named entity 'regulatory T cells' named entity 'leukocyte' named entity 'ACE2 receptor' named entity 'atherosclerosis' named entity 'ROS' named entity 'neutrophil' named entity 'blood clots' named entity 'vascular permeability' named entity 'myocardial infarction' named entity 'upregulation' named entity 'CVD' named entity 'inflammatory processes' named entity 'vascular tone' named entity 'Ang II' named entity 'platelet' named entity 'Ang-II' named entity 'receptor' named entity 'extrinsic and intrinsic' named entity 'endothelial cells' named entity 'pathogen' named entity 'kidney' named entity 'infection' named entity 'COVID-19' named entity 'cardiometabolic' named entity 'lung diseases' named entity 'COVID19' named entity 'mitochondrial respiratory chain' named entity 'systemic infection' named entity 'heart failure' named entity 'SARS-CoV-2' named entity 'virus' named entity 'COVID-19' named entity 'immune complex'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software